Form 4: United Therapeutics' CEO Rothblatt Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4 Filing
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 19 and July 22, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, the Chairperson and CEO of United Therapeutics, engaged in transactions involving the exercise and sale of stock options.
- These transactions occurred on July 19 and July 22, 2024.
- The transactions were executed under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- On both July 19 and July 22, 3,600 stock options were exercised at a price of $129.49 per share.
- Following these transactions, Rothblatt directly owns 86,669 stock options.
- The sales were executed in multiple trades at varying prices, with weighted average prices reported for each transaction.
- Rothblatt also indirectly owns shares through various family trusts.
- The 10b5-1 trading plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions by an insider under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 723,869 stock options that expire December 31, 2024, or August 31, 2024.
Industry Context
This filing is a routine disclosure of insider transactions, which are common among executives of publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares in the open market.
- The impact is likely to be minimal given the pre-arranged nature of the trading plan.
Key Dates
| Date | Description |
|---|---|
| 12/31/2014 | Original date exercisable for stock options |
| 08/04/2023 | Date the 10b5-1 trading plan was entered into by the reporting person |
| 07/19/2024 | Date of stock option exercise and sale transactions |
| 07/22/2024 | Date of stock option exercise and sale transactions |
| 07/23/2024 | Date of signature for the Form 4 filing |
| 08/31/2024 | End date of the 10b5-1 trading plan (or earlier exhaustion of options) |
| 12/31/2024 | Expiration date of the tranche of 723,869 stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.